ONCLIVE JULY 25 , 2024 .
Existe una Necesidad Insatisfecha de Pacientes de SEGUNDA LÍNEA y POSTERIORES Que Hayan Recibido QUIMIOTERAPIA e INMUNOTERAPIA Para su ENFERMEDAD .
IFINATAMAB DERUXTECAN Fue Bien Tolerado y Provocó una Actividad DURADERA en Pacientes con SCLC Pretratados, lo Que Sugiere Que Puede Abordar la Falta de Medicamentos Eficaces en SEGUNDA LÍNEA .
EN LA FASE III SMALL CELL LUNG CÁNCER SEGUNDA LINEA IFINATAMAB DERUXTECAN SE COMPARA FRENTE A TOPOTECAN / LURBINECTEDIN / AMRUBICIN .
Dr Sands On The Evolving Role Of ADCs In SCLC Management .
Jacob Sands, MD, Oncology Medical Director, International Patient Center, Dana-Farber Cancer Institute ; Assistant Professor, Harvard Medical School, Discusses The Evolution of The Role of Antibody-Drug Conjugates (ADCs) in The Treatment of Patients With SMALL CELL LUNG CÁNCER ( SCLC ) .
ADCs represent an Exciting Advancement in Oncology, Particularly in The Management of Non–small cell lung cancer (NSCLC) And SCLC, Sands Begins . One Promising Agent, IFINATAMAB DERUXTECAN, Has Elicited an OVERALL RESPONSE RATE of 52.4% (95% CI, 29.8%-74.3%) in Previously Treated Patients with SCLC, as Well as a Median PFS of 5.6 Months (95% CI, 3.9-8.1) . Although This Agent is Not a Definitive Therapy, Its Development Marks a Significant Step Forward in The SCLC Field, Offering Durable Outcomes For This Aggressive Disease And Expanding Available Options, Sands Explains . ...
**************
**********
******
IFINATAMAB DERUXTECAN Fue Bien Tolerado y Provocó una Actividad DURADERA en Pacientes con SCLC Pretratados, lo Que Sugiere Que Puede Abordar la Falta de Medicamentos Eficaces en SEGUNDA LÍNEA .
The Antibody-Drug Conjugate ( ADC ) IFINATAMAB DERUXTECAN ( I-DXd; DS-7300 ) WAS WELL Tolerated And Elicited Durable Activity in Patients With Heavily Pretreated SMALL CELL LUNG CÁNCER ( SCLC ), Suggesting That Its Continued Development May Address The Lack Of Effective Therapeutics in The SECOND-LINE And Beyond For This Disease, According To Melissa L. Johnson, MD.
.jpeg)
